High doses of aqueous protein antigens induce a form of immunological tolerance in which interleukin 2 (Ib2)-and interferon 3' (IFN-T)-secreting T helper type 1 (Thl) cells are inhibited, but IL-4-secreting (Th2) cells are not. This is manifested by reduced proliferation of antigenspecific T cells upon in vitro restimulation, and marked suppression of specific antibody responses of the immunoglobulin (Ig)G2a, IgG2b, and IgG3 isotypes, but not of IgG1 and IgE. The role of the immunomodulatory cytokine I1-4 in this model of unresponsiveness to protein antigens has been examined. Administration of tolerizing antigen itself primes splenic CD4 + T cells for secretion of lymphokines, both I1.2 and I1-4. Neutralization of I1-4 in vivo with the anti-I1-4 antibody 11Bll during tolerance induction augments IFN-y production by T cells of tolerant mice, and reverses the suppression of IgG2a, IgG2b, and IgG3. This blockade of I1.4 function does not, however, restore the proliferative responses of T cells, suggesting that reduced T cell proliferation is due to direct T cell inactivation or anergy. Inhibiting the activity of IL-4 in vivo also inhibits the expansion of antigen-specific Th2-1ike cells, which are resistant to the induction of unresponsiveness. Thus, the immunologic consequences of high-dose tolerance are due to a combination of clonal T cell anergy and I1.4-mediated immune regulation.
T he induction of peripheral T cell tolerance to specific antigens is a well-known phenomenon (for reviews, see references [1] [2] [3] . Tolerance in an individual may be due to several mechanisms, including deletion or anergy of antigenspecific lymphocytes and suppression by other cells or factors, all of which have been implicated in tolerance to self and foreign antigens. In vitro studies have shown that cloned lines of CD4 + T lymphocytes can be rendered anergic by antigen stimulation in the absence of costimulatory signals (4) . This form of anergy is associated with a block in I1.-2 gene transcription, and, as a result, a reduction in proliferative responses. Anergy is readily induced in I1.2-and IFN-3,-secreting (Thltype) helper clones, but not in I1.4-, I1.5-, and IL-10-secreting (Th2-type) clones (5, 6) .
Recently, inhibition of specific and nonspecific immune responses has been recognized as a regulatory action of many cytokines. For instance, I1.4 and IFN-3' reciprocally antagonize the actions of each other on B cells (7) , and each inhibits the differentiation of naive T cells into secretors of the other cytokine (8) (9) (10) . TGF-~ also antagonizes the development of I1.4-secreting T cells (11) . I1.10 suppresses the activation of T cells, notably Thl cells, by inhibiting the function of macrophages as APC (12, 13) . Thus, in many experimental systems, cytokines serve as potent downmodulators of lymphocyte differentiation and activation, with I1.4 exerting an inhibitory effect on Thl-like responses, and IFN-3' doing the same to Th2-1ike responses. Selective expression of cytokines is also known to be important in the hyporesponsive state associated with many chronic microbial diseases, particularly leprosy (14) and various parasitic infections (15) . In these diseases, I1.4 and I1.10 expression are associated with suppressed cellmediated immunity, whereas IFN-3' expression is found in more reactive lesions.
These observations raise the possibility that cytokine regulation plays a role in antigen-specific tolerance in vivo. Such a possibility has not been formally explored to date. Several regimens for inducing tolerance to foreign antigens in vivo have been described, including the administration of large quantities of aqueous antigens (high-dose tolerance), providing antigens in ways that selectively target costimulator-deficient APC, and antigen feeding (oral tolerance). Previously, we and others have shown that in a model of high-dose tolerance, parenteral administration of soluble protein antigens to adult mice induces unresponsiveness in Thl-but not Th2-type lymphocytes (16, 17) . In this model, immunization and in vitro restimulation show that antigen-specific T cell proliferation and production of I1-2 and IFN-y are inhibited, but secretion of IL-4 is unaffected, The antigen-specific antibody repertoire shows changes consistent with a selective inhibition of Thl cells. Serum levels of antigen-specific IgM, IgG1, and IgE, isotypes unaffected or sustained by I1.4, are normal or even increased, while specific IgG2a, IgG2b, and IgG3, isotypes that are enhanced by IFN-y and suppressed by Ib4 (7, 18, 19) , are greatly reduced. Direct tolerization of antigenspecific B cells does not occur in this system.
We have now explored the contribution of IL-4 to the establishment of high-dose tolerance, and its effect on lymphokine-producing T cells in tolerized animals. An IL-4 antagonist augments antibody responses in tolerant animals and increases IFN-3' production by T cells, but does not prevent the block in the IL-2-dependent proliferation of antigen-specific Thllike cells. In addition, neutralization of IL-4 during tolerance induction reveals that IL-4 serves as a growth and differentiation factor for Th2 cells in vivo, and accounts for their expansion in tolerized animals. Thus, high-dose tolerance in vivo may be due to a combination of clonal anergy of Thl cells and inhibition mediated by Th2-derived cytokines.
Materials and Methods
Antigens, Cytokines, and Antibodies. TNP-conjugates of OVA, BSA, and rabbit gamma globulin (Sigma Chemical Co., St. Louis, MO) were prepared as described previously (19 On day 17, mice were bled for serum and killed, and draining lymph nodes were collected. In experiments analyzing splenic responses, spleens were harvested on experiment day 8 before immunization of the mice.
For anti-IL-4 mAb treatments, animals were given 2 mg of HPLC-purified 11Bll in PBS on days 0 and 4 of the experiment, and 1 mg on day 8. Control animals were given an equivalent volume of PBS. This dose of 11Bll has been shown to block 99% of the IL-4 dependent, nematode-induced primary IgE response in mice (22) .
Cell Preparation, Cultures, and Lymphokine Bioassays. Lymphocyte suspensions from draining lymph nodes or spleen were prepared by grinding tissue through sterile wire mesh; for lymph node cells, lymphocytes from two mice in each treatment group were pooled. CD4 § cells were depleted from splenocytes using two rounds of anti-CD4 antibodies, GK1.5 (23) and RL172 (24) , and guinea pig complement (Cedarlane Laboratories, Hamilton, On-1 Abbreviation used in this paper: PPD, purified protein derivative. tario, Canada). This procedure effectively depleted >98% of CD4 § cells. For proliferation assays, 4 • 105 cells were cultured in 0.2 ml RMPI 1640 supplemented with 2 mM r-glutamine, penicillin, streptomycin, nonessential amino acids, sodium pyruvate, 10 mM Hepes (all from Gibco Laboratories, Grand Island, NY), 5 x 10 -5 M 2-ME, and 10% heat-inactivated FCS (HyClone Laboratories, Logan, UT), at 37~ in 96-well flat-bottomed microculture plates in 5% CO2. OVA or PPD was added as indicated in the figures; proliferation was measured on day 3 of culture by [3HITdR incorporation. For lymphokine production assays, 6 x 105 lymph node cells or 8 • 105 spleen cells were cultured in medium alone or medium with antigen as indicated, and supernatants were collected at 48 or 72 h. IL-2 levels were measured by using the IL-2/IL-4-sensitive indicator line HT-2 in the presence of the blocking antibody 11Bll (10 #g/ml) as described (16) . I1_,4 levels were determined using the II~4-dependent indicator line CT.4S (25; kindly provided by Drs. R. Seder and W. E. Paul, National Institutes of Health) in the presence of the anti-IL-2 antibody $4B6 (1:1,000 dilution of ascites) to assure specificity. In this assay, halfmaximal stimulation of CT4S cells is seen with 10-20 U/ml of rlL-4, the units having been originally defined by the suppliers on the basis of B cell costimulation assays. IFN-3, activity was measured by inhibition of proliferation of the B lymphoma line WEHI 279 as described (16) . Concentrations in units/milliliter were determined using purified recombinant cytokines as standards, and were based on concentrations provided by the suppliers. Standard deviations were all <10% of sample values.
Assays for Anti-TNP Antibodies. Serial dilutions ofsera were analyzed for TNP-specific antibodies by ELISA. Titers of anti-TNP IgM, IgG1, IgG2a, IgG2b, and IgG3 isotypes were determined using plates coated with TNP-BSA, and isotype-specific alkaline phosphatase-conjugated developing reagents as described previously (19) . TNP-specific IgE was measured using a pan-IgE capture reagent, followed by a sandwich ELISA of serum, TNP-rabbit gamma globulin, and anti-rabbit Ig reagents as described previously (16) .
Results and Discussion

Tolerogenic Antigen Stimulates Lymphokine-producing T Cells.
If IL-4 plays a role in the induction or maintenance of highdose tolerance, then tolerogenic antigens should themselves stimulate IL-4 production. To test this, aqueous TNP-OVA was injected into mice intraperitoneally at doses previously shown to induce tolerance (16) . Splenocytes were isolated and examined for lymphokine production upon restimulation with OVA in culture. As shown in Table 1 , at high cell numbers splenocytes from TNP-OVA-pretreated mice secreted low but detectable, antigen-inducible levels of IL-4 and II.-2 upon restimulation with OVA. Proliferative responses of these cells were minimal (not shown), and mice given aqueous TNP-OVA did not contain detectable anti-TNP IgG1 or IgG2a antibodies in their sera (16) .
It has recently been demonstrated that an important source of IL-4 is a non-B, non-T population of cells that belong to the mast cell/basophil lineage and release lymphokine in response to Fc receptor-mediated signaling (26, 27) . It was possible that aqueous antigens induced Igs capable of sensitizing Fc receptors on these cells, facilitating Ib4 release on subsequent exposure to antigen. Two approaches were used to establish the cellular source of IL-4. First, depletion of CD4 + cells from splenocytes was found to completely abolish antigen-induced secretion of both IL-2 and Ib4 (Table 1) . Second, TNP-BSA was shown to be incapable of stimulating IIA secretion by splenocytes from TNP-OVA-pretreated mice (Table  1) . These results indicate that crosslinking bound anti-TNP Ig on inflammatory cells is not the mechanism of IL-4 release, and that lymphokine production is carrier specific, as expected of a T cell response. Thus, even tolerogenic aqueous protein antigens at high doses are capable of "priming" splenic 11.-2-and IL-4-producing CD4 § T cells.
Anti-IL,4 Antibody Enhances Specific Antibody Production in Tolerized Mice but Does Not Prevent the Block in T Cell Proliferation.
The above results raised the possibility that high-dose tolerance may, at least in part, be due to the effects of IL-4, which is stimulated by tolerogenic antigen. Were this the case, specifically antagonizing the effects of IL-4 ought to reduce or prevent tolerance. To test this, mice were treated with aqueous TNP-OVA at tolerogenic doses on days 1, 3, and 5 of the experiment, given 2 mg of the anti-Ib4 mAb 11Bll on days 0 and 4 and 1 mg on day 8, and were immunized with antigen in adjuvant on day 8. Serum antibody levels and T cell responses to in vitro restimulation were determined 9 d later. Titers of serum anti-TNP antibody of different isotypes are shown in Fig. 1 . As previously reported (16) , pretreatment with tolerogenic antigen markedly suppressed the production of IgG2a, IgG2b, and IgG3, all of which are inhibitable by IIr4 (18, 19) , but did not inhibit IgG1 and IgE, which are enhanced by or dependent on IL-4 ( Fig. 1, left) . When tolerance was induced in a parallel set of mice treated with 11Bll, the production of IgG2a, IgG2b, and IgG3 was greatly increased (Fig. 1, right) . Mice given the lower tolerogenic doses and 11Bll had titers two-to fivefold higher for these isotypes than even control mice that were immunized without prior administration Of tolerogen. At the highest dose of tolerogen, the 11B11-treated mice showed reduced production of these isotypes compared with mice not pretreated with tolerogenic antigen. This is probably due to the induction of anergy in T cells, which results in reduced expansion of helper T cells in vivo. Anti-IL-4 antibody treatment abolished specific IgE production, demonstrating that IL-4 was effectively neutralized by 11Bll in vivo. 11Bll treat- Mice were pretreated with PBS or aqueous TNP-OVA at the indicated doses on days 1, 3, and 5. Splenocytes were collected on day 8, and cultured at 8 x 10 s per well in medium alone, or with antigen at the indicated concentrations (/zg/ml). CD4+ T cells were depleted from splenocytes by treatment with anti-CD4 antibodies and complement, and also cultured at 8 x 10 s per wall (CD4 dep.). Lymphokine levels were determined from supernatants taken from cultures on day 2 (IL-2) or day 3 (IL-4). Data are means of concentrations of lymphokines from two mice per group. SE were <10% of sample values in all cases. Results are from one representative experiment out of three. " NT, not tested. Mice were tolerized with TNP-OVA at the indicated doses and half were treated with 11Bli, before subcutaneous immunization with TNP-OVA in CFA. Immune lymph node cells (6 x 105) were cultured with medium, OVA, or PPD at the concentrations indicated. Supematants from day 2 cultures were analyzed for IL-2; supernatants taken on day 3 were analyzed for IL-4 and IFN-% Data are means of lymphokine concentrations. alone, but showed no change in IL-2 secretion (Table 2) . In three experiments, administration of tolerogenic antigen (200-1,000 gg) reduced subsequent in vitro IL-2 production by immune T cells by an average of 86.5%, and reduced IFN-3, production by 89.4%, compared with T cells from immunized (and not tolerized) mice. In mice given tolerogen and 11Bll, II.-2 production remained reduced by 91%, whereas IFN-3' levels were restored to 43% of controls. In all three experiments, I1-4 secretion by immune T cells was almost completely suppressed by prior administration of llBll. Thus, neutralizing the effects of I1-4 at the time of induction of tolerance in Thl cells has two consequences on lymphokineproducing T ceils: it prevents the concomitant expansion of I1-4-secreting Th2 cells, and it enhances IFN-7 production. Anti-I1-4 does not prevent the inhibition of I1-2 secretion by T ceils from tolerized mice, suggesting that the block in I1-2 is a direct effect of the tolerogen, presumably from a form of T cell anergy. Surviving, anergized Thl-like cells are nonetheless secreting IFN-7, reminiscent of findings from in vitro experiments where T cell anergy causes near complete inhibition of II-2 secretion and only partial inhibition of IFN-7 secretion (4). Based on the results described above, the following sequence of events in tolerance induced by high doses of aqueous antigens can be envisioned. Administration of aqueous antigen induces clonal anergy in tolerance-sensitive, I1-2-producing cells of the Thl subset, a direct consequence of antigen recognition. Tolerance in these cells may be due to antigen presentation by APC such as resting B cells or macrophages, which lack necessary costimulators (29) . Anergy of Thl cells is manifested by a block in clonal expansion in vivo, which is assayed by reduced I1-2 production and proliferation upon restimulation with antigen. At the same time, aqueous antigen stimulates I1-4 production by CD4* T cells, enhancing the differentiation of Th2-1ike cells that are resistant to tolerization. Subsequent immunization with antigen and adjuvant induces further expansion of Th2-1ike cells, which serve as a source of continuing I1-4 production. This I1-4 may mediate several of the immunologic changes seen in tolerant mice. First, IL-4 drives the production of IgG1 and IgE, and inhibits the antigen-induced switching to and secretion of IgG2a, IgG2b, and IgG3 isotypes. Second, Ib4 inhibits IFN-'y production by any residual anergic Thl cells that have retained the ability to secrete IFN-7. IL-4 has been shown to inhibit IFN-3' production by T cells in vitro (30, 31) . Finally, the Th2 cells that are expanded by I1-4 may secrete other cytokines, such as I1-10, that further suppress Thldependent responses (12, 13) .
These findings indicate that there are multiple mechanisms of tolerance operating at the organismal and the cellular level. The phenomenon of tolerance in the intact animal, as measured by antibody responses, is attributable in part to the suppressive actions of I1-4, whereas the tolerogen-induced inhibition of Thl cells is a form of cellular unresponsiveness or anergy that is largely independent of exogenous cytokines. The roles of cytokines in other models of tolerance remain to be explored. Identifying the mechanisms of tolerance has important implications for the design of therapeutic strategies to inhibit pathologic immune responses. High-dose tolerance may be especially effective for disorders caused by Thl-mediated delayed-type hypersensitivity reactions. Additionally, in highdose tolerance, selective activation of Th2-type T cells may account for skewing immune reactions towards hyporesponsire states, as has been found in chronic microbial infections with high antigenic loads. Antagonizing the cytokine activities augmented in such diseases may be one way of ameliorating these conditions.
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